Market research
APOP Cellect Biotechnology Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- 0.0%
- Beta
- 1.88
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US15116C3007
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- 0.0%
- Beta
- 1.88
About
About Cellect Biotechnology Ltd
As of October 28, 2021, Cellect Biotechnology Ltd. was acquired by Quoin Pharmaceuticals, Inc., in a reverse merger transaction. Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the APOP discussion.
5 years, 4 months ago
Cellect Biotechnology Ltd is currently in a long term uptrend where the price is trading 22.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Cellect Biotechnology Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 16.3% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 122.7% to $-5M since the same quarter in the previous year.
Based on the above factors, Cellect Biotechnology Ltd gets an overall score of 3/5.